Javascript must be enabled to continue!
Interpretable precision medicine for acute myeloid leukemia
View through CrossRef
Precision medicine (PM) is a branch of medicine that defines a disease at a higher resolution using genetic and other technologies to enable more specific targeting of its subgroups. Because of its uses in clinical treatment and diagnostics, this field exemplifies the modern era of medicine. PM looks for not just the right drug, but also the right dosage and treatment regimen. PM encounters a variety of challenges, which will be explored in this dissertation. Large-scale sensitivity screens and whole-exome sequencing experiments (WES) have fostered a new wave of targeted treatments based on finding associations between drug sensitivity and response biomarkers. These experiments with the aid of state-of-the-art artificial intelligence (AI) algorithms are opening new therapeutic opportunities for diseases with unmet clinical needs. It has been proved that AI is capable of predicting novel personalized treatments based on complex genotypic and phenotypic patterns in tumors. The scientific community should make an effort to make these algorithms to be interpretable to humans so that the results could be easily approved by the medical regulators. The purpose of this thesis is to apply AI algorithms for precision oncology that are highly accurate, while guaranteeing that the predictions are interpretable by humans. This work is divided in three main sections. The first section comprises a new methodology to increase the predictive power of the discovery of novel treatments in large-scale screenings by exploiting that some biomarkers tend to appear in many treatments. This fact is called hub effect in gene essentiality (HUGE). Content of this section was published in [1]. The second section contains a novel interpretable AI method -called multi-dimensional module optimization (MOM)- that associates drug screening with genetic events and proposes a treatment guideline. Content of this section was published in [2]. Finally, the third section includes a detailed comparison of different recently published algorithms that attempt to overcome the barriers proposed by today's precision medicine. This study also includes two novel algorithms specifically designed to solve the challenges of applicability to clinical practice: Optimal Decision Tree (ODT) and Multinomial Lasso. The characterization of Interpretable Artificial Intelligence as approach with strong potential for use in clinical practice is one of the study's most significant achievements. We presen tunique methods for PM that are highly interpretable, and we summarize the needs that could be considered for constructing interpretable AI. We are confident that this method will transform the way PM is addressed, bridging the gap between AI and clinical practice.
Title: Interpretable precision medicine for acute myeloid leukemia
Description:
Precision medicine (PM) is a branch of medicine that defines a disease at a higher resolution using genetic and other technologies to enable more specific targeting of its subgroups.
Because of its uses in clinical treatment and diagnostics, this field exemplifies the modern era of medicine.
PM looks for not just the right drug, but also the right dosage and treatment regimen.
PM encounters a variety of challenges, which will be explored in this dissertation.
Large-scale sensitivity screens and whole-exome sequencing experiments (WES) have fostered a new wave of targeted treatments based on finding associations between drug sensitivity and response biomarkers.
These experiments with the aid of state-of-the-art artificial intelligence (AI) algorithms are opening new therapeutic opportunities for diseases with unmet clinical needs.
It has been proved that AI is capable of predicting novel personalized treatments based on complex genotypic and phenotypic patterns in tumors.
The scientific community should make an effort to make these algorithms to be interpretable to humans so that the results could be easily approved by the medical regulators.
The purpose of this thesis is to apply AI algorithms for precision oncology that are highly accurate, while guaranteeing that the predictions are interpretable by humans.
This work is divided in three main sections.
The first section comprises a new methodology to increase the predictive power of the discovery of novel treatments in large-scale screenings by exploiting that some biomarkers tend to appear in many treatments.
This fact is called hub effect in gene essentiality (HUGE).
Content of this section was published in [1].
The second section contains a novel interpretable AI method -called multi-dimensional module optimization (MOM)- that associates drug screening with genetic events and proposes a treatment guideline.
Content of this section was published in [2].
Finally, the third section includes a detailed comparison of different recently published algorithms that attempt to overcome the barriers proposed by today's precision medicine.
This study also includes two novel algorithms specifically designed to solve the challenges of applicability to clinical practice: Optimal Decision Tree (ODT) and Multinomial Lasso.
The characterization of Interpretable Artificial Intelligence as approach with strong potential for use in clinical practice is one of the study's most significant achievements.
We presen tunique methods for PM that are highly interpretable, and we summarize the needs that could be considered for constructing interpretable AI.
We are confident that this method will transform the way PM is addressed, bridging the gap between AI and clinical practice.
Related Results
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Myosin-IIa Is Required for Leukemia Cell Extravasation and Its Inhibition Reduces Leukemia Dissemination and Prolongs Survival in a Mouse Model of Acute Lymphoblastic Leukemia
Myosin-IIa Is Required for Leukemia Cell Extravasation and Its Inhibition Reduces Leukemia Dissemination and Prolongs Survival in a Mouse Model of Acute Lymphoblastic Leukemia
Abstract
Background: Leukemia affects approximately 45,000 people each year in the USA with more than 20,000 fatalities. Many leukemia patients experience initial re...
ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia
ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia
Differentiation therapies achieve remarkable success in acute promyelocytic leukemia, a subtype of acute myeloid leukemia. However, excluding acute promyelocytic leukemia, clinical...
ecision Farming and Predictive Analytics in Precision Farming and Predictive Analytics in Precision Farming and Predictive Analytics in Precision Farming and Predictive Analytics in Precision Farming and Predictive Analytics in Precision Farming and Predi
ecision Farming and Predictive Analytics in Precision Farming and Predictive Analytics in Precision Farming and Predictive Analytics in Precision Farming and Predictive Analytics in Precision Farming and Predictive Analytics in Precision Farming and Predi
The scope of sensor networks and the Internet of Things spanning rapidly to diversified domains but not limited to sports, health, and business trading. In recent past, the sensors...
Activation Of EphrinB2/EphB4 Influences Myeloid Leukemia Cell Migration and Invasion
Activation Of EphrinB2/EphB4 Influences Myeloid Leukemia Cell Migration and Invasion
Abstract
Eph receptors and ephrin ligands are cell-surface molecules capable of bidirectional signaling that control cell-cell interactions, migration and invasion. ...
Cytogenetic profile of Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia in Northern Pakistan
Cytogenetic profile of Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia in Northern Pakistan
Objective: To determine the frequencies of different cytogenetic abnormalities in patients of Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia in Northern Pakistan.
Methods...
STAT3 Mutations in Large Granular Lymphocytic Leukemia
STAT3 Mutations in Large Granular Lymphocytic Leukemia
Abstract
Abstract 1606
Introduction:
Large granular lymphocytic leukemia (LGL leukemia) is a rare lymphoprolifera...
Nature Products Enhance NKG2D Ligands Expression of CD123+CD34+CD38− Leukemia Stem Cells for Stimulating Cytotoxicity of NKG2D+ Cells to Themselves
Nature Products Enhance NKG2D Ligands Expression of CD123+CD34+CD38− Leukemia Stem Cells for Stimulating Cytotoxicity of NKG2D+ Cells to Themselves
Abstract
CD123+CD34+CD38− leukemia cells regarded as leukemia stem cells, not only refractory to chemotherapeutics but also resistant to immune response such as cyto...

